VeraDermics Insider John W. Childs Buys 294,000 Shares at $17 Amid Phase‑3 Trial Hype—Is the Market Overlooked?
Insider buy of VeraDermics shares at $17 signals confidence ahead of Phase 3 results; 1 % stake may hint at undervaluation and potential upside.
3 minutes to read